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Cloning Type IV-B CRISPR System Into a Target Plasmid
CRISPR Systems As Adaptive Immune 
Systems in Microorganisms
• Viruses outnumber the bacteria they infect 10 to 1
• Bacteria have evolved highly specialized immune 
systems known as CRISPR-Cas systems. 
• These diverse systems encode as memories (spacers) 
copies of the nucleic acids which previously infected 
the cell. 
• The transcription of the CRISPR locus creates a 
complementary RNA (crRNA) which can bind to new 
invaders, marking them for termination by Cas 
proteins. 
Type IV--B System 
• Type IV systems are newly discovered and have only 
recently been categorized as Class I systems (using multi 
subunits to bind crRNA)
• There are two types of Type IV systems 
• Type IV - B systems are especially unique because they do 
not encode the CRISPR locus that characteristically is 
found on any system. Instead it encodes only the Cas 
proteins.  
• Characterizing the Type IV-B system could lead to 
understanding it’s function and role in the cell. 
Figure 4: PCR Amplification of Type 
IV-B System (18 February 2020)
Figure 5: Vector (Target Plasmid) 
Digest (30 April 2020)
Type IV-A
Type IV-B
Figure 3: Restriction Enzyme Cloning
Type IV-B as an Anti-CRISPR
• Our hypothesis is that the Type IV-B system will act as an 
anti-CRISPR, a system that will act to block the function of 
another CRISPR function, to allow the bacteria to “choose” 
if an invasive plasmid should be degraded or kept.. 
Results
• A successful colony PCR showed the E. coli which had taken up the transformed plasmid 
and so those colonies were chosen for sequencing
• Sequencing results (Figure 6)  show the cloning was successful. The top line is the Type IV-
B template with the several sequencing reactions below. Black color indicates the sequence 
matches the template. Red zones show sequences that didn’t match. However, all red 
zones overlap with black zones and so we know the entire system was cloned successfully.
Methods
PCR Cleavage & Amplification of Type IV–B System 
Double Digest of Target Plasmid
Ligation & Amplification of Open Plasmid & Type IV–B
Colony PCR & Sequencing
To transplant the Type IV-B system into the 
target plasmid we performed restriction enzyme 
cloning, as shown in Figure 3. The success of 
our project is dependent on the sequencing 
results.
Future Directions
• The above-described plasmid curing assay is underway and we 
hope to see results from that, shortly. 
• Ancillary proteins 
found close to the 
system in native 
plasmids may be 
integral to its function. 
We can test this by 
cloning the ancillary 
proteins onto our new 
plasmid 
• This has been our 
current project for the 
past couple of months. 
• The bacteria grown with 
the transformed Type 
IV-B sequence on the 
plasmid is predicted to 
have growth because 
the Type IV-B will block 
the Type IV-A from 
destroying the plasmid 
and therefore retaining 
the antibiotic resistance 
gene and allow colonies 
to grow.
• A plasmid curing assay 
will be performed using 
our cloned plasmid to 
determine if this is the 
case. 
• However, if we do not 
see the activity we are 
expecting to see, this 
could indicate that 
ancillary proteins 
integral to the Type IV-
B system.
Figure 7: Plasmid Curing Assay with and 
without ACR (Anti-CRISPR) gene
Figure 8: Cloning process for ancillary 
proteins
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Figure 6: Sequencing results for Type IV-B in target plasmid
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